Skip to content
Research Article Open access CC BY 4.0

Nilotinib-Induced Thromboembolic Events: A Case Study

Zahra Kmira, Ben Yahya Noura, Guermazi Monia, Fathallah Neila, Atig Amira, Chembah Wafa, Thabet Maissa, Zaier Monia, Ben Youssef Yosra, Haifa Regaieg, Khelif Abderrahim

Journal of Advances in Biology & Biotechnology · pp. 596–602 · Published 23 Jan 2025

10.9734/jabb/2025/v28i11912

Abstract

Nilotinib has significantly improved the treatment of chronic myeloid leukemia (CML) by offering enhanced efficacy and tolerability. However, studies have revealed a concerning link between nilotinib and an increased risk of thromboembolic events, even compared to other tyrosine kinase inhibitors (TKIs). This case report presents a forty-four-year-old male with CML treated with nilotinib, who developed dyslipidemia and multiple arterial occlusive events, including renal thrombosis and carotid artery atheroma. The potential mechanisms underlying nilotinib-induced thromboembolic events are endothelial cell dysfunction, altered lipid metabolism, and pro-inflammatory and prothrombotic effects. Identifying preexisting cardiovascular risks and implementing proactive measures may aid in reducing the occurrence of thromboembolic events in high-risk patients treated with nilotinib.

Nilotinib thromboembolic events outcome

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

10

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.